Telehealth Provider Stopped Prescribing GLP-1? Here's What to Do Next
By the Weight Loss Provider Guide research team · Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers.
Last verified: May 19, 2026 · Next review: June 19, 2026
If your telehealth provider stopped prescribing GLP-1 medication — refill canceled, pharmacy can't fill, or the platform quietly pulled the plug — take a breath. You're not alone, and you have more options than the panic is telling you.
Bottom line: When your telehealth provider stopped prescribing GLP-1, your safest first move is to find out why access stopped before you pick a new provider. The reason — FDA compounding rules, pharmacy policy, insurance denial, a clinical concern, or a business pivot — decides your next step. For most disrupted weight-loss patients in 2026, the most stable path is checking FDA-approved weight-management options first: Wegovy, Zepbound, or the new Foundayo pill.
What just happened — do this first
| What just happened? | Do this today | Don't do this |
|---|---|---|
| Your provider removed compounded refills | Ask why in writing. Save the message. Request your records. | Don't guess your next dose. |
| The pharmacy stopped filling | Ask if it's law, supply, policy, or a sourcing issue. | Don't switch to an unknown online seller. |
| Insurance denied or dropped coverage | Get the denial letter and the prior authorization criteria. | Don't assume every GLP-1 path is out of reach. |
| You're running low (under 2 weeks) | Book a clinician review today. Use the 7-day plan below. | Don't stretch doses, skip weeks, or buy "research" peptides. |
| The provider just disappeared | Pull your records before you sign up anywhere new. | Don't pay a new provider without confirming the pharmacy and price. |
What we actually verified for this page
We pulled directly from primary sources:
- ✓FDA April 1, 2026 compounding policy clarification
- ✓FDA February 6, 2026 statement on non-FDA-approved GLP-1 drugs
- ✓FDA March 3, 2026 — 30 warning letters to telehealth companies
- ✓FDA April 30, 2026 proposal to exclude semaglutide/tirzepatide/liraglutide from 503B bulks list
- ✓FDA April 1, 2026 Foundayo approval
- ✓Current public pricing pages for Ro, NovoCare, LillyDirect, Walgreens Virtual Healthcare, Sesame Care, Eden, and others (verified May 19, 2026)
- ✓KFF analyses on Medicare and Medicaid GLP-1 coverage
- ✓Compiled public/provider-stated compounded-vs-branded status for 15 major GLP-1 telehealth providers (verification method noted in the table below)
This page is informational. It's not medical advice and it doesn't replace a licensed clinician. We're an independent comparison resource for GLP-1 telehealth providers, and we may earn a commission when readers use certain provider links — that doesn't change which paths we recommend.
Your 7-day action plan
What to do in the first 7 days after your GLP-1 refill stops — matched to how much supply you have left.
Day 1. Count exact doses you have left. Take a photo of the bottle, pen, or vial label. Save every message from your provider, the pharmacy, and your insurance.
Day 1. Send your current provider the script in the next section. Request (a) a prescription transfer to a different pharmacy, (b) a brand-name bridge prescription, OR (c) full release of your medical records.
Day 1–2. If you already know you want an FDA-approved path, check your coverage on Ro or look up cash-pay options at NovoCare Pharmacy and LillyDirect.
Day 3–4. Complete intake with your chosen provider. Ask about shipping timelines, any prior-authorization step, and what they do if you run out before the new prescription arrives.
Day 5–7. Continue follow-up. If shipping or PA is delayed, ask the new provider for a brand-name bridge prescription or a manufacturer cash-pay route while you wait.
Days 1–2. Pull your records and verify the medication name, formulation type, dose in milligrams, last fill date, and prescribing clinician.
Days 3–5. Compare 2–3 paths using the four-path framework below.
Days 5–7. Run a free insurance check. Ro's GLP-1 Insurance Coverage Checker takes about a minute — Ro says it contacts your insurance and emails you a personalized coverage report.
Days 7–10. Submit intake with your chosen provider.
Week 1. Read this guide. Decide which of the four paths fits.
Week 1–2. If insurance might cover Wegovy, Zepbound, or Foundayo, start the prior authorization process. Ro's insurance concierge says PA work typically takes 1–3 weeks after a clinician approves you for treatment.
Week 2–3. Onboard with your chosen provider.
Week 3–4. Receive medication and re-establish ongoing care.
Don't want to figure this out alone?
Take the Free 60-Second Continuity Quiz →We'll point you at the path that fits your supply, your insurance, and your budget.
The exact message to send your current provider
Copy this. Paste it into the patient portal or email. Send it today.
Subject: My GLP-1 refill status — need confirmation and records
I see that my GLP-1 refill has stopped or changed. Can you confirm the exact reason: FDA/compounding policy, pharmacy availability, insurance, clinical eligibility, state availability, or something else?
Please also send my full transfer packet so I can continue care safely. Specifically, I need:
- —Current medication name, formulation type (FDA-approved or compounded), and concentration
- —Current dose in milligrams (not units) and the dosing schedule
- —Last fill date and last dose date
- —Prescribing clinician's name and contact
- —Dispensing pharmacy name and address
- —Recent labs on file
- —Any diagnosis codes used for insurance
- —Any prior authorization documents or denial letters
Thank you.
Why did my telehealth provider stop prescribing GLP-1?
Short answer: Many telehealth providers changed or stopped compounded GLP-1 access after the FDA declared the tirzepatide and semaglutide shortages resolved (December 19, 2024 and February 21, 2025, respectively) and ended shortage-related enforcement discretion. But not every stop is FDA-related — pharmacy policy, insurance changes, state-availability rules, clinical reasons, and business-model pivots all play a role.
Here's what changed, in order:
FDA declared the tirzepatide shortage resolved.
FDA declared the semaglutide shortage resolved. Once a drug is no longer in shortage, pharmacies can't routinely make copies of it.
FDA's FY2025 enforcement reporting described dozens of warning letters to telehealth companies selling misbranded compounded products.
FDA announced its intent to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded products, naming Hims & Hers in the announcement.
FDA issued a direct warning letter to MEDVi (Letter #721455) citing "Same active ingredient as Wegovy® and Ozempic®" claims and labeling that suggested MEDVi was the compounder when it wasn't.
FDA issued 30 warning letters to telehealth companies. Primary violations: claims implying sameness with FDA-approved products and obscuring product sourcing.
Hims & Hers announced a strategic shift toward FDA-approved GLP-1 medications and said it would no longer promote compounded GLP-1s in marketing.
FDA approved Foundayo (orforglipron), the first oral non-peptide GLP-1 from Eli Lilly, giving clinicians a new FDA-approved pill option for weight management.
FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Public comment open through June 29, 2026.
Some providers continue patient-specific 503A compounding when a clinician documents a significant clinical difference. Many providers have pivoted to FDA-approved brand-name medications.
Which kind of GLP-1 access problem do I have?
Five things can cause a GLP-1 access interruption, and each one leads to a different next step. Identify your situation, then jump to the matching path below.
| Your specific problem | Most likely reason | First move today | Best next path |
|---|---|---|---|
| Provider stopped offering compounded sema or tirzepatide | FDA compounding rules tightened after shortage resolved | Get the reason in writing and pull your records | Check FDA-approved options first; compounding only if clinician documents specific need |
| Pharmacy stopped filling | Pharmacy changed policy, lost a supplier, or stepped back from compounded GLP-1 | Ask whether it's law, supply, quality, licensing, or prescriber-side | Transfer care to a clinician who can evaluate FDA-approved options or appropriate alternatives |
| Insurance denied or stopped covering Wegovy, Zepbound, Ozempic, Mounjaro, or Foundayo | Formulary change, employer benefits change, PA renewal, or weight-loss exclusion | Get the denial letter and the PA criteria in writing | Appeal where realistic, employer HR request, cash-pay manufacturer route, or alternate FDA-approved indication review |
| Provider stopped for clinical reasons | Side effects, labs, contraindications, pregnancy plans, GI/pancreatitis concerns | Ask exactly what concern triggered the stop | PCP, obesity medicine, or endocrinology follow-up — don't restart or switch on your own |
| Telehealth company pivoted away from compounded entirely | Business decision after FDA enforcement (Hims, others) | Ask whether they'll transfer you to brand-name on the same platform | If yes, take it. If no, switch to a provider that offers FDA-approved options |
| Tempted by "research peptides" | Panic plus price shock | Do not buy no-prescription GLP-1s | Use only licensed clinicians and state-licensed pharmacies — FDA explicitly warns against products labeled "for research purposes" |
Can I still get GLP-1 medication online legally in 2026?
Yes, but the legitimate route involves a licensed clinician, a real medical evaluation, and either an FDA-approved medication or a lawful patient-specific compounded option when clinically appropriate. The unsafe route — no-prescription sellers, "research peptides," counterfeit products — is exactly what FDA enforcement is targeting.
The three legitimate online routes:
- 1Telehealth with FDA-approved medication. A licensed clinician evaluates you and prescribes Wegovy, Zepbound, Foundayo, Ozempic, or Mounjaro. The medication ships from a state-licensed pharmacy or is picked up locally.
- 2Manufacturer direct. NovoCare Pharmacy (Wegovy, Ozempic) and LillyDirect (Zepbound, Mounjaro, Foundayo) dispense directly with a valid prescription — no telehealth membership required.
- 3Patient-specific compounded prescription. A licensed clinician documents a clinical reason an FDA-approved drug doesn't meet your medical need. This route is narrower than it was during the shortage — and per FDA guidance, lower cost alone is not a clinical reason.
What are my four paths if my GLP-1 provider stopped refills?
Four legitimate paths: stay on compounded GLP-1 with a different provider when a clinician determines it's appropriate, switch to FDA-approved brand-name medication (now far more affordable than most people realize), try the new FDA-approved oral pill Foundayo, or take a structured break under clinician care. The right path depends on cost, your insurance, whether you want FDA-approved certainty, and whether you prefer injection or pill.
| Path | Best for | Typical monthly cost | Stability |
|---|---|---|---|
| 1. Stay on compounded (new provider) | Documented patient-specific clinical need | $179–$329/mo | Lower — depends on provider survival and FDA action |
| 2. Switch to FDA-approved brand | Long-term stability, insurance access, freedom from compounding rules | $25–$449/mo depending on insurance and drug | Highest |
| 3. Try Foundayo (FDA-approved oral pill) | People who want a pill, not a shot, and FDA-approved certainty | $149+/mo (LillyDirect intro through Dec 31, 2026) | High |
| 4. Structured break under clinician care | Financial breather, evaluating progress, planning a pregnancy | $0 medication cost during break | High |
Can I stay on compounded GLP-1 with a different provider?
The honest part first. Compounded GLP-1 is not the safe, stable lane it was in 2024. Hims and Hers have pivoted toward FDA-approved options. Multiple federal lawsuits are working through the courts. The FDA's April 30, 2026 proposal could narrow access further after the June 29 comment period closes. If long-term stability is what you care most about, Path 2 is the safer choice.
Compounded path eligibility reality check
| Reason | Does it support patient-specific compounding? | What to ask your clinician |
|---|---|---|
| Documented allergy to an inactive ingredient in the FDA-approved product | Yes, when documented | "Can you note the specific allergic reaction and the excipient in my chart?" |
| Required dose not commercially available (titration, microdose) | Sometimes, when documented | "Is this dose actually unavailable from the FDA-approved product?" |
| FDA-approved drug currently unavailable at any pharmacy | Sometimes, when verified | "Have we confirmed the FDA-approved option isn't available?" |
| Lower price than brand-name | No, per FDA guidance | "Are there other reasons that fit my situation?" |
| Insurance won't cover brand-name | No, per FDA guidance, on its own | "What are my coverage and cash-pay alternatives?" |
| You prefer a sublingual or oral format | Depends — Foundayo is now an FDA-approved oral option | "Would Foundayo fit my medical profile?" |
Path 1 fits if:
- You and your clinician identified a patient-specific need an FDA-approved product doesn't meet
- You understand the product is not FDA-approved and access may change
- You can switch again if your new provider also pivots
- You don't have insurance that would cover brand-name
Path 1 does NOT fit if:
- You want FDA-approved certainty
- You have commercial insurance that might cover brand-name
- You're on Medicare or Medicaid
- The only reason you want compounded is lower cost
7 questions to ask any new compounding-capable provider
- 1Which compounding pharmacy fills your prescriptions? (You want a name, not "our pharmacy partner.")
- 2Is that pharmacy 503A or 503B?
- 3Do you have backup pharmacies if your primary one stops?
- 4Can your clinician write a brand-name bridge prescription if compounded access disappears?
- 5How is the medication labeled — in milligrams, not just units?
- 6What's your cancellation policy if I need to leave fast?
- 7Has your company received an FDA warning letter? If yes, what's been corrected?
Eden — the compounded option we'd point to first
If Path 1 fits your situation and you want a broad-default provider that also offers branded options as a backup, Eden is the most balanced fit we found. Eden lists licensed-provider coordination, no monthly membership fee on the compounded program, HSA/FSA eligibility on its branded Wegovy and Zepbound options, and same-price-at-every-dose on most compounded products. Eden also publicly discloses that compounded therapies are not reviewed or approved by the FDA.
What we like for this specific scenario: if your compounded access disappears again, Eden can route you to FDA-approved Wegovy or Zepbound on the same platform instead of forcing you to switch providers a second time.
Check Eden Availability in Your State →We may earn a commission if you continue with Eden.
Should I switch to FDA-approved brand-name GLP-1?
For most disrupted weight-loss patients in 2026, switching to FDA-approved brand-name medication is the most stable long-term path. Cash-pay prices have dropped dramatically. The price gap between compounded and brand-name has narrowed sharply.
The 2026 cash-pay pricing reality
Verify before signing up — intro offers have expiration dates and dose-tier conditions.
| Medication | Manufacturer direct (cash-pay) | With commercial insurance + savings card |
|---|---|---|
| Wegovy pill | $149/mo for 1.5 mg and 4 mg through NovoCare; the 4 mg offer runs through August 31, 2026 (then $199/mo) | as low as $25/mo |
| Wegovy injection | $199/mo for 0.25 mg and 0.5 mg starting doses for two monthly fills through June 30, 2026; then $349/mo; $399/mo for Wegovy HD 7.2 mg | as low as $25/mo |
| Ozempic (T2D; off-label for weight) | $199/mo for 0.25 and 0.5 mg for two monthly fills through June 30, 2026; then $349/mo for 0.25, 0.5, and 1 mg; $499/mo for 2 mg | as low as $25/mo |
| Zepbound KwikPen | $299/mo for 2.5 mg, $399/mo for 5 mg, $449/mo for 7.5–15 mg through manufacturer offer; 45-day refill window applies | as low as $25/mo |
| Foundayo | $149/mo for 0.8 mg, $199/mo for 2.5 mg, $299/mo for 5.5 mg and 9 mg; $299/mo for 14.5 mg and 17.2 mg if refilled within 45 days, otherwise $349/mo; through Dec 31, 2026 | varies |
| Mounjaro (T2D; off-label for weight) | Insurance-led; cash-pay varies by pharmacy and channel | as low as $25/mo with manufacturer savings card |
The four ways to access FDA-approved GLP-1
- 1Manufacturer direct: NovoCare Pharmacy (Wegovy, Ozempic) or LillyDirect (Zepbound, Mounjaro, Foundayo). No membership. If you already have a valid prescription from your previous provider, you may be able to use it here directly.
- 2Telehealth with insurance concierge: Ro does the prior-authorization paperwork for you and connects you to commercial insurance coverage if available. Membership and medication billed separately.
- 3Telehealth with provider choice: Sesame Care lets you pick a clinician and offers month-to-month or annual plans, with Costco-member pricing on some doses of Wegovy and Ozempic.
- 4Pharmacy-anchored: Walgreens Virtual Healthcare charges $49 per video visit and lets you pick up at any Walgreens.
Ro — our pick for FDA-approved access with insurance help
If you have commercial insurance and want a single platform to handle prior authorization, prescription management, and one of the broadest published FDA-approved GLP-1 menus we verified, Ro is the cleanest fit for this disruption scenario.
- ✓Access to Wegovy pill, Wegovy injection, Ozempic, Zepbound KwikPen, Zepbound pen, and Foundayo
- ✓A dedicated insurance concierge that handles prior-authorization paperwork
- ✓Ro's GLP-1 Insurance Coverage Checker — contacts your insurance and sends a personalized coverage report by email
- ✓Cash-pay pricing that matches LillyDirect and NovoCare directly
- ✓Licensed provider check-ins and structured care included with membership
Get started for $39 for the first month, then as low as $74/month with annual plan (or $149/month month-to-month). Medication cost is billed separately.
We may earn a commission if you continue with Ro.
Is Foundayo a real FDA-approved oral GLP-1 option?
Yes. Foundayo (orforglipron) is an FDA-approved oral GLP-1 from Eli Lilly, approved April 1, 2026. It's the first oral non-peptide GLP-1 receptor agonist — no injections, no food or water timing restrictions, and a 24-month dating period. LillyDirect lists Foundayo starting at $149/month for 0.8 mg, with intro pricing through December 31, 2026.
This is the path most readers don't know exists. If your provider stopped compounded oral semaglutide and you don't want to go back to a weekly injection, Foundayo is the FDA-approved oral option that didn't exist a year ago.
Why it matters for the disruption audience
- Daily pill, not a weekly injection
- FDA-approved — no compounding rule risk
- No food or water timing restrictions like Rybelsus has
- Currently priced competitively with compounded options at intro doses
Honest weight-loss comparison
ATTAIN-1 trial: 11.1% average weight loss at 72 weeks (intention-to-treat). Less than tirzepatide injections (~20%) and semaglutide injections (~14–15%). If maximum weight loss is the top priority, Zepbound is still strongest. If avoiding needles or FDA-approved oral certainty matters more, Foundayo is the legitimate choice.
If Foundayo fits your preferences, Ro carries Foundayo at LillyDirect-matched pricing with insurance concierge support:
Check Foundayo on Ro →Should I take a structured GLP-1 break under clinician care?
A temporary pause may be a reasonable option for some weight-loss-only patients, but it's a clinical decision — not a self-prescribed one. The risk changes significantly if you use a GLP-1 for diabetes, cardiovascular risk reduction, sleep apnea, or another medical condition.
Path 4 fits if:
- You can't afford any current options and only used a GLP-1 for weight management
- You want to evaluate weight stability before deciding next steps
- You're planning a pregnancy in the next 6–12 months (Wegovy labeling advises stopping at least 2 months before planned pregnancy)
- You're hitting a side-effect ceiling and need clinician input
Path 4 does NOT fit if:
- You use a GLP-1 for type 2 diabetes
- You're on a GLP-1 for cardiovascular risk reduction in known heart disease
- You're on a GLP-1 for sleep apnea or another approved indication
- You have severe side effects that need clinician input first
The maintenance plan to discuss with your clinician
- Follow-up appointment scheduled before you stop
- Weight trend monitoring for the first 3 months
- A protein and fiber focused eating plan
- Resistance training to preserve muscle
- Adequate sleep and stress management
- Possible bridge medications if appropriate: phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), or metformin off-label
- A restart plan if your clinician recommends one
Which GLP-1 providers are still operating in May 2026?
Public/provider-stated and verified status of 15 major GLP-1 telehealth providers as of May 19, 2026.
Verification key: V = verified on provider's public page or FDA source · P = provider-stated, not independently verified · N = news/reporting-sourced · L = court/legal filing-sourced
| Provider | Compounded status (May 2026) | FDA-approved brand options | Notable disclosure | Source |
|---|---|---|---|---|
| Ro | Pivoted toward FDA-approved focus | Yes — Wegovy pill, Wegovy injection, Ozempic, Zepbound pen, Zepbound KwikPen, Foundayo | Cancellation in-app; no government insurance coordination | V |
| Hims | Strategic shift March 9, 2026 toward FDA-approved; no longer promoting compounded GLP-1s; limited compounded semaglutide for clinical-necessity cases | Yes — Wegovy pill, Wegovy injection, Ozempic via Novo Nordisk partnership | FDA named Hims in Feb 6, 2026 enforcement statement | V |
| Hers | Same strategic shift as Hims | Yes — same Novo Nordisk-partnered access | Same FDA enforcement context as Hims | V |
| Eden | Continues both compounded and branded operations | Yes — Wegovy and Zepbound flagged HSA/FSA eligible | Publicly discloses compounded products are not FDA-approved | V |
| MEDVi | Continuing compounded operations | Limited — primarily compounded | Received FDA warning letter Feb 20, 2026 (#721455) citing "Same active ingredient as Wegovy and Ozempic" claims | V (FDA warning letter) |
| Mochi Health | Continues compounded operations | Yes — also offers branded with insurance | Defending active federal litigation tied to compounded GLP-1 marketing | N/L |
| Henry Meds | Continues compounded operations | Limited brand-name path | Active litigation context per news reporting | N/L |
| Sesame Care | Branded-only, FDA-approved focus | Yes — Wegovy, Zepbound, Ozempic, Mounjaro, Foundayo, Saxenda; Costco-member pricing on some doses | Member-driven subscription | V |
| Yucca Health | Continues compounded operations | Limited | BNPL payment options listed; verify cancellation terms | P |
| SHED | Continues compounded oral/sublingual options | No — compounded only | Not a recommendation for FDA-approved Foundayo intent | P |
| Trim Rx | Continues compounded operations | Limited | Mixed third-party reviews on billing and cancellation | P |
| WeightWatchers Med+ | FDA-approved focus | Yes — Wegovy, Zepbound | Membership-based | V |
| Walgreens Virtual Healthcare | FDA-approved focus | Yes — Wegovy pill, Wegovy injection, Foundayo, Zepbound KwikPen | $49 video visit; pickup at any Walgreens | V |
| NovoCare Pharmacy | N/A — direct manufacturer self-pay | Yes — Wegovy pill from $149/mo, Ozempic from $199/mo intro | No telehealth membership | V |
| LillyDirect | N/A — direct manufacturer self-pay | Yes — Zepbound $299–$449/mo, Foundayo from $149/mo intro | No telehealth membership | V |
Status changes happen monthly in this category. We re-verify and date-stamp every row each month. Rows marked P or N/L need additional direct verification before any provider-specific transition decision. Spot something outdated? Email [email protected].
What should Medicare or Medicaid patients do first?
Medicare Part D is generally prohibited from covering medications used specifically for weight loss, but it can cover GLP-1s when prescribed for diabetes, cardiovascular risk reduction in heart disease, or other approved indications. According to KFF's analysis, the Medicare GLP-1 Bridge program is scheduled to run from July 1, 2026 through December 31, 2027 for eligible beneficiaries, while CMS has indefinitely delayed Medicare Part D implementation of the BALANCE Model. Medicaid BALANCE implementation begins May 2026. Medicaid obesity-drug coverage varies by state — only 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service as of January 2026.
If you're on Medicare:
- Talk to your prescriber about whether you qualify for an FDA-approved indication other than obesity (type 2 diabetes, cardiovascular risk in heart disease, sleep apnea)
- Ask your clinician whether you may qualify for the Medicare GLP-1 Bridge program
- Most cash-pay telehealth programs (including Ro) cannot coordinate with Medicare
- Manufacturer savings cards typically exclude government insurance beneficiaries
If you're on Medicaid:
- Check your specific state's Medicaid formulary — coverage varies significantly
- Most states require a BMI threshold and step therapy
- Cash-pay telehealth is usually not the right path for Medicaid patients
- See our Medicaid GLP-1 providers page for state-by-state options
What should I do first if I have commercial insurance?
If you have commercial insurance, run a free coverage check before paying cash for anything. With a successful prior authorization and a manufacturer savings card, your monthly cost for Wegovy, Zepbound, or Foundayo can drop to as low as $25 — less than the cheapest compounded option.
Denial type matrix
| Denial type | What it means | Is appeal realistic? | What to request |
|---|---|---|---|
| Prior authorization expired | Your PA renewal lapsed | Yes — usually fixable with documentation | New PA submission with current labs and BMI |
| Missing BMI or comorbidity documentation | The PA didn't include required clinical data | Yes — fixable with proper documentation | Doctor's office resubmits with full clinical picture |
| Step therapy requirement | Plan requires trying older medications first | Sometimes — depends on prior trial documentation | Records of prior failed therapies (Contrave, Qsymia, phentermine) |
| Formulary exclusion (Wegovy not on preferred list) | Plan prefers a different drug | Sometimes — formulary exceptions are available | Formulary exception request |
| Employer obesity-drug exclusion | Your employer excluded weight-loss meds from the plan | Rarely — usually structural | Employer HR request or alternate route (cash-pay, different indication) |
| Government plan limitation | Medicare Part D excludes weight-loss-only use | No — by statute | Diabetes/CVD/OSA indication review with prescriber |
The 5-step coverage check
- 1Find your PBM. Look at your insurance card for one of these names: Caremark, Express Scripts, OptumRx, Humana Pharmacy, or your plan's own pharmacy benefit manager.
- 2Look up the formulary. Check whether Wegovy, Zepbound, or Foundayo is on your plan's preferred drug list, and what tier it sits on.
- 3Check the PA criteria. Your plan will usually require a BMI threshold, documented lifestyle attempts, and sometimes one or more comorbidities (high blood pressure, sleep apnea, prediabetes).
- 4Submit the PA. Your prescriber's office submits the paperwork through CoverMyMeds, SureScripts, or your PBM's portal.
- 5If denied, identify the denial type and appeal where it's realistic. Use the matrix above.
Ro's GLP-1 Insurance Coverage Checker handles steps 1–2 in about a minute. If you become a Ro Body member, their insurance concierge handles steps 3–5. That concierge is the single feature that makes Ro worth the membership fee for most insured patients.
Use Ro's Free Coverage Checker →No commitment. Free personalized report. We may earn a commission if you continue with Ro.
What to avoid — even when you're desperate
Avoid four things even when panic makes them tempting: buying GLP-1s from unregulated online sellers, stockpiling extra doses to self-titrate, switching medications without clinician guidance, and trusting any provider that prescribes without taking your medical history or labs. The FDA explicitly warns against products falsely labeled "for research purposes only" or "not for human consumption."
| Red flag | Why it matters |
|---|---|
| No prescription required | Real GLP-1s require a licensed clinician |
| "For research purposes only" | FDA warns these products are unknown quality and may be harmful |
| "Not for human consumption" | Same warning — these have been sold to consumers anyway |
| No pharmacy name on the label | You can't verify the source |
| Spelling errors or wrong addresses | FDA flags this as a fraudulent product signal |
| Warm injectable shipment or inadequate cold pack | FDA has received complaints; warm shipments may have lost potency |
| Seller giving dose instructions in "units" | Dosing errors with compounded injectables have caused hospitalizations |
| "FDA-approved compounded" or "generic Ozempic" | Compounded products are not FDA-approved. Generic Ozempic does not exist. |
| Foreign API claims without verification | The FDA's import alert flags GLP-1 active ingredients with quality concerns |
The FDA's public safety notice on unapproved GLP-1s details fraudulent labeling, dosing errors leading to hospitalizations, and warm-shipment quality issues.
How to switch from compounded to brand-name safely
Switching from a compounded GLP-1 to an FDA-approved brand-name medication isn't a one-to-one swap. Compounded doses don't always map cleanly to brand-name doses, and starting too high can cause severe nausea or worse side effects. Your new clinician needs your current medication name, formulation type, exact dose in milligrams, last dose date, and side-effect history before making the call on starting dose.
What your new clinician needs
- Product name and formulation type (compounded oral, compounded injection, sublingual, etc.)
- Active ingredient (semaglutide, tirzepatide, liraglutide)
- Concentration and units of the product
- Dose in milligrams (not just "units" — this is the critical one)
- Last dose date
- Side effects you've experienced
- Weight trend
- Medical history and current medications
- Recent labs
- Pharmacy label photo (if you have it)
The switching reference table
| Your current situation | What to ask your new clinician |
|---|---|
| On compounded semaglutide injection | "Based on my current mg dose, what Wegovy injection or Wegovy pill dose should I start at?" |
| On compounded tirzepatide injection | "Should I transition to Zepbound at my current dose, or restart lower?" |
| On compounded oral or sublingual product | "Is there an FDA-approved oral option that fits — Wegovy pill, Foundayo, or Rybelsus off-label?" |
| On compounded medication for diabetes (not weight) | "Should this transition through diabetes care rather than weight-loss telehealth?" |
| Off medication for several weeks | "Do I need to restart at a lower dose since I've had a gap?" |
What real users say about the switch
We don't manufacture testimonials, and we don't quote without verification. Ro publishes testimonials from Body Program members in a dedicated section, and Ro discloses on its own page that the members shown were paid for their testimonials. That disclosure is the right standard — when you're reading provider testimonials anywhere on the internet, check for it.
For a more independent signal on a specific provider, look at Trustpilot or similar review platforms and read the recent reviews — both the positive and the negative ones. Focus on process-oriented feedback (how the onboarding went, whether the insurance concierge actually helped, whether cancellation was clean) rather than medical results, because medical results are individual and not transferable.
12 questions to ask any new GLP-1 provider before transferring
When you transfer GLP-1 care, ask about more than price. The most expensive mistakes happen when patients sign up for a low first-month price without understanding total cost, pharmacy source, dose escalation, cancellation terms, or what happens if policy shifts again. Get these 12 answers in writing before you pay.
- 1Are you prescribing FDA-approved medication, compounded medication, or both?
- 2What medication names and formulations are available in my state?
- 3Is medication cost separate from the membership or program fee?
- 4What does my first month cost — including any consultation fee?
- 5What does my fourth month cost — once intro promos end?
- 6Does the price change as my dose increases?
- 7Which pharmacy fills my prescription? (Name, not "our partner.")
- 8Is that pharmacy state-licensed? Can I verify it on my state's pharmacy board website?
- 9What labs or records do you require before prescribing?
- 10How do you handle missed doses, dose changes, or transfer patients?
- 11What's the cancellation and refund policy?
- 12What happens if your business model changes or FDA actions affect my access?
Frequently asked questions
Will my prescription expire when my telehealth provider shuts down?
A platform shutdown does not automatically cancel every prescription, but validity, remaining refills, and transferability depend on what was written, your remaining refills, state rules, pharmacy policy, and whether the prescriber stays reachable. Pull your records and prescription details immediately so you have something to transfer.
Can I get my prescription transferred to another pharmacy?
Yes, in most cases. Contact your current prescribing provider and request a transfer to a specific pharmacy. If your provider isn't responding, request a copy of your records — under HIPAA, you have a federal right to access protected health information in your designated record set from covered entities, generally within 30 days. Bring those records to a new clinician.
What if my pharmacy stopped filling my GLP-1?
Ask the pharmacy whether the stop was caused by supply, pharmacy policy, licensing, sourcing, FDA-related risk, or prescriber policy. Your prescription itself may still be valid — pharmacies and prescriptions are separate. Once you know the reason, your clinician can either transfer the prescription to another licensed pharmacy or switch you to an FDA-approved alternative.
How long can I safely go without a GLP-1 dose?
That depends on the medication, dose, time missed, your diabetes status, your side effects, and why the medication was stopped. Don't make this decision on your own — ask your clinician or a pharmacist how to handle a refill gap or missed dose. Don't double doses, stretch doses, or restart at an old dose after a long gap without medical input.
Is compounded GLP-1 still legal in 2026?
Yes, in narrower circumstances. Patient-specific 503A compounding remains legal when a clinician documents a significant clinical difference from the FDA-approved product for an individual patient. The FDA does not consider lower cost or insurance access as a valid clinical reason. Mass 503B compounding of semaglutide, tirzepatide, and liraglutide is being restricted — the FDA's April 30, 2026 proposal would formally remove these from the 503B bulks list pending the June 29, 2026 comment-period closure.
Which telehealth providers stopped prescribing compounded GLP-1?
Hims & Hers announced a strategic shift toward FDA-approved GLP-1s on March 9, 2026, and said it would no longer promote compounded GLP-1s in marketing while still allowing limited compounded access in clinically necessary cases. Several smaller providers halted production after receiving FDA warning letters. As of May 2026, Mochi Health, Henry Meds, MEDVi, Eden, SHED, Yucca Health, and Trim Rx have continued compounded operations, though FDA enforcement and litigation could change this.
What does brand-name Wegovy or Zepbound actually cost in 2026?
Less than you think. Through manufacturer self-pay programs: Wegovy pill starts at $149/month for 1.5 mg and 4 mg (NovoCare, 4 mg through Aug 31, 2026), Wegovy injection starts at $199/month for 0.25/0.5 mg starting doses (NovoCare, through June 30, 2026), Zepbound KwikPen starts at $299/month for 2.5 mg (LillyDirect), and Foundayo starts at $149/month for 0.8 mg (LillyDirect, through Dec 31, 2026). With commercial insurance and a manufacturer savings card, the cost can drop to as low as $25/month. Verify before signing up.
I'm on Medicare — will Medicare cover GLP-1?
Medicare Part D is generally prohibited from covering medications used specifically for weight loss, but it can cover GLP-1s for type 2 diabetes, cardiovascular risk reduction in heart disease, and sleep apnea. The Medicare GLP-1 Bridge program is scheduled to run from July 1, 2026 through December 31, 2027 for eligible beneficiaries. CMS has indefinitely delayed Medicare Part D implementation of the BALANCE Model. Ask your clinician whether you may qualify for the Bridge.
Is Foundayo the same as compounded oral semaglutide?
No. Foundayo (orforglipron) is an FDA-approved oral, non-peptide GLP-1 receptor agonist from Eli Lilly, approved on April 1, 2026. Compounded oral semaglutide is a different product made by compounding pharmacies and is not FDA-approved. They should not be treated as equivalent.
I have less than a week of medication left — what should I do today?
Message your current provider for either a brand-name bridge prescription or a transfer of your prescription. If you already have a valid prescription from your shuttered provider, NovoCare Pharmacy and LillyDirect can sometimes dispense quickly without telehealth onboarding. If you don't have a valid prescription, sign up with one of the FDA-approved-focused providers and tell them about your supply timeline.
Can I keep my current dose if I switch from compounded to brand-name?
Sometimes, but don't assume. Compounded doses don't always map cleanly to FDA-approved dose strengths, and starting too high can cause severe side effects. Your new clinician will determine the appropriate brand-name starting dose based on your current regimen, the time you've been off (if any), and your tolerance.
What if my insurance just stopped covering my GLP-1?
Get the denial letter in writing. Identify the denial type using the matrix above. Denials caused by missing documentation or expired PA are usually fixable. Denials caused by employer exclusions or government-plan rules are usually structural. Ro's insurance concierge handles appeals for Ro Body members; you can also work with your prescriber's office directly.
Can I buy GLP-1 without a prescription?
No legitimate path allows this. The FDA explicitly warns consumers not to purchase GLP-1s without a prescription, especially products labeled "for research purposes" or "not for human consumption." These have been linked to dosing errors, hospitalizations, and fraudulent labeling. Use a licensed clinician and a state-licensed pharmacy only.
What's the fastest safe next step if my GLP-1 access stopped?
Three things: get your records from your current provider, identify which of the four paths fits your situation, and connect with a licensed clinician through either our continuity quiz or directly with a provider that matches your path. Don't make medication decisions in panic mode — but don't delay so long that you run out either.
Still not sure which GLP-1 program is right for you?
We built this guide to end your search. Four paths still means a choice — and the right choice depends on details that are personal to your situation: how much medication you have left, what you can afford, your insurance, your state, your dose history, and whether you prefer injection or pill.
Take our free 60-second matching quiz. Seven questions. Personalized action plan. No signup required.
Start the 60-Second GLP-1 Continuity Quiz →How we built this guide
We're an independent comparison resource for GLP-1 telehealth providers. We don't accept payment to change rankings. Affiliate links exist on this page but they don't influence which paths we recommend.
Primary sources used:
- FDA regulatory documents: All compounding policy clarifications, warning letters, and drug approval announcements linked above with dates verified.
- Manufacturer pages: NovoCare Pharmacy, NovoCare Wegovy page, LillyDirect
- Provider pricing pages: Ro, Sesame Care, Eden, Walgreens Virtual Healthcare, and others — verified May 19, 2026
- Coverage analysis: KFF on Medicare and Medicaid; CMS Medicare GLP-1 Bridge
- News reporting: STAT News, Pharmacy Times, CNBC, WIRED, Reuters
- Clinical context: FDA prescribing information; FDA's unapproved GLP-1 safety information
What "verified" means here. A claim is verified when the source is a primary regulatory document (FDA, CMS, KFF), a current manufacturer or provider page (with verification date), or a clinical authority. Provider table rows are labeled with the verification method (V/P/N/L). Forum and review content was used for voice-of-customer language only — not for medical, safety, or regulatory claims.
This guide is updated monthly. GLP-1 access is changing fast. We re-verify the provider status table and pricing every month. Spot something outdated? Email [email protected].
This is not medical advice. GLP-1 medications require a clinician's evaluation. Always consult a licensed clinician before starting, stopping, or switching any prescription medication.